182 related articles for article (PubMed ID: 33581736)
1. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.
Gretler SR; Finno CJ; Kass PH; Knych HK
BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses.
Knych HK; Baden RW; Gretler SR; McKemie DS
Biochem Pharmacol; 2019 Oct; 168():184-192. PubMed ID: 31295464
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
4. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Wu X; Yuan L; Zuo J; Lv J; Guo T
Eur J Clin Pharmacol; 2014 Jan; 70(1):57-63. PubMed ID: 24077935
[TBL] [Abstract][Full Text] [Related]
5. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.
Vevelstad M; Pettersen S; Tallaksen C; Brørs O
Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365
[TBL] [Abstract][Full Text] [Related]
6. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.
Molanaei H; Carrero JJ; Heimbürger O; Nordfors L; Lindholm B; Stenvinkel P; Odar-Cederlöf I; Bertilsson L
Eur J Clin Pharmacol; 2010 Mar; 66(3):269-73. PubMed ID: 19940985
[TBL] [Abstract][Full Text] [Related]
7. Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses.
Gretler SR; Finno CJ; McKemie DS; Kass PH; Knych HK
Vet Anaesth Analg; 2020 Sep; 47(5):694-704. PubMed ID: 32654915
[TBL] [Abstract][Full Text] [Related]
8. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
9. On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
[TBL] [Abstract][Full Text] [Related]
10. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
11. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.
Lötsch J; Skarke C; Schmidt H; Rohrbacher M; Hofmann U; Schwab M; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):35-48. PubMed ID: 16413240
[TBL] [Abstract][Full Text] [Related]
12. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?
He YJ; Brockmöller J; Schmidt H; Roots I; Kirchheiner J
J Anal Toxicol; 2008 Mar; 32(2):178-82. PubMed ID: 18334103
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, adverse effects and effects on thermal nociception following administration of three doses of codeine to horses.
Knych HK; Stucker K; Gretler SR; Kass PH; McKemie DS
BMC Vet Res; 2022 May; 18(1):196. PubMed ID: 35614473
[TBL] [Abstract][Full Text] [Related]
16. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.
Radford H; Simpson KH; Rogerson S; Johnson MI
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31141989
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and metabolism of codeine in humans.
Vree TB; Verwey-van Wissen CP
Biopharm Drug Dispos; 1992 Aug; 13(6):445-60. PubMed ID: 1391681
[TBL] [Abstract][Full Text] [Related]
18. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
[TBL] [Abstract][Full Text] [Related]
19. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1.
Mortimer O; Persson K; Ladona MG; Spalding D; Zanger UM; Meyer UA; Rane A
Clin Pharmacol Ther; 1990 Jan; 47(1):27-35. PubMed ID: 2295216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
